Trade name of the product



Active substance (INN)



Pharmaceutical form

Solution for injection



Active ingredient:

Vinpocetine 5,0 g
Ascorbic acid 5,0g
Tartaric acid 3,0g
Benzyl alcohol 10,0g
Sodium metabisulfite 0,2g
Sorbitol 100,0g
Water for injection up to 1000 ml



Clear, colorless or slightly greenish-yellowish solution


Pharmacotherapeutic group

Drugs for treatment of cerebral circulatory disorders and migraine


Pharmacological properties

Cerebra vasodilating means is improved cerebral circulation. It causes a slight decrease in systemic blood pressure, increasing cerebral blood vessels, increasing blood flow and improving the supply of oxygen to the brain and glucose. Increases resistance to hypoxia of the brain cells, facilitating the transport of oxygen and substrates of energy supply to the tissues (due to reduced affinity of erythrocytes to him, strengthening the absorption and metabolism of glucose, toggle it to energetically more favorable aerobic). It promotes tissue accumulation of cyclic adenosine adenozinmonophosphat acid, phosphodiesterase inhibition and stimulation of adenylate cycles and increase of catecholamines in the brain tissues (dopamine and norepinephrine). Vasodilating action is related to a direct relaxant effect on vascular smooth muscle mainly in the brain. The drug does not cause the phenomenon of "steal", but primarily increases blood flow to the ischemic area of the brain, without changing the blood supply intact areas. Improves micro circulation in the brain by reducing platelet aggregation, reduce blood viscosity, increased erythrocyte deform ability.



For parenteral administration the volume of distribution (Vd) - 5,3 l / kg. The half-life (T1 / 2) - 4, 74-5 hours easily penetrates the blood-tissue barriers (including the blood-brain barrier).
Bio transformation in the liver to apovincaminic acid, hydroxy-vinpocetine gidroksiapovinkaminovoy acid, dihydroxy-vinpocetine-glycinate. Major metabolite - apovincaminic acid - has a pharmacological activity.
Vinpocetine excreted in the urine in unchanged form (slightly) and as metabolites.


Indications for use

Acute and chronic ischemic (transient ischemia, progressing stroke, completed stroke, post-stroke). Neurological and psychiatric disorders in patients with cerebrovascular insufficiency (memory impairment, dizziness, aphasia, apraxia, motor disorders, headache). Encephalopathy (hypertension, post-traumatic). Vazonegativ menopausal symptoms. Vascular eye disease (a degenerative disease of the choroids, retina, or macula, partial occlusion of the arteries, secondary glaucoma). Hearing loss of vascular or toxic origin, senile deafness, Meniere's disease, kohleovestibuliar neuritis, tinnitus, vertigo labyrinthine origin.


Dosing and Administration

In the acute phase of the disease slowly intravenously (maximum infusion rate - 80 drops / min) 10-20 mg in 500-1000 ml of isotonic sodium chloride solution. If necessary, the maximal dose is increased during 3-4 days until - 1 mg / kg / day. The treatment course is about 10-14 days.
After achieving clinical improvement pass on the admission of the drug by mouth, 5-10 mg three times a day. Maintenance Dose - 5 mg 3 times per day for a long time. The dose should be gradually reduced before the abolition of the dose should be gradually reduced.


Side effects

From the nervous system and sensory organs: dizziness, headache, insomnia, drowsiness, weakness, feeling the heat.
Cardio-vascular system and blood (blood, hemostasis): slowing intraventricular conduction; ST-segment depression and prolongation of the interval QT, hypotension, tachycardia, arrythmia.
For part of the gastrointestinal tract: dry mouth, nausea, heartburn.
For the skin: redness, sweating, thrombophlebitis at the injection site.
Other: allergic reactions.



Hypersensitivity, pregnancy, lactation, infancy (due to lack of clinical data), expressed as ischemic heart disease, severe arrhythmia, and labile blood pressure and low vascular tone, the first days after cerebral hemorrhagic stroke, increased intracranial pressure.
Not allowed subcutaneous, intramuscular and jet / in the introduction.
With care - patients receiving antihypertensive drugs or medications that increase the interval QT, and patients with poor tolerance of vinca alkaloids small (Vincaminor) and suffering from liver failure.



Increases the risk of hemorrhagic complications during heparin therapy. A solution for injection vinpocetine pharmaceutically incompatible with heparin.



When administered parenterally diabetics must monitor blood glucose levels, as in the solution contains sorbitol.
In hemorrhagic stroke, parenteral administration is possible only after the acute symptoms subside (usually 5 -7 days).
At the time of treatment should stop breastfeeding. In the presence of long QT syndrome, or use of drugs while provoking lengthening of the interval QT, ECG monitoring is required. A sufficient number of observations on the use of the drug in pediatric practice. Should not be used during the drivers of vehicles and people skills relate to the high concentration of attention. The drug should be stored out of reach of children and do not use after the expiration date.



Symptoms: a metallic taste in the mouth; thirst, pronounced tremor, dysarthria, ataxia.
Treatment: gastric lavage, activated charcoal, symptomatic treatment.


Form release

Solution for injection of 0.5%, 2 ml ampoules.


Storage conditions

In the dark place at a temperature not higher than 25 C.


Expiration date

2 years.


Terms of supply of pharmacies




Local anaesthetic drugs
Nootropic drugs
Antihypertensive drugs
Drugs for a parenteral food
Medicines applied at poisonings and intoxications
Medicines for metabolic processes correction
Medicines for peripheric blood circulation
Mineral drugs, microcells
Salt solutions
Analgesic and antispasmodic drugs
Nonsteroidal anti-inflammatory drugs